ÂÜÀòÂÒÂ×

Frank Karbe has over twenty-five years of financial and life-sciences expertise and most recently served as President and Chief Financial Officer of Myovant Sciences (NYSE: MYOV). Prior to Myovant, Mr. Karbe served as Executive Vice President and Chief Financial Officer at Exelixis, Inc., (NASDAQ: EXEL) where he drove the biopharma company’s transformation from discovery to commercialization.

Earlier in his career, Mr. Karbe worked as an investment banker for Goldman Sachs & Co. focusing on corporate finance and mergers and acquisitions in the life sciences industry. He has previously served on the Board of Directors of Aduro Biotech, Arbutus Biopharma Corporation, and Kolltan Pharmaceuticals, Inc.

Mr. Karbe holds a Diplom-Kaufmann (MBA) from the WHU Otto Beisheim School of Management in Koblenz, Germany.